# Magnetic melamine cross-linked polystyrene-alt-malic anhydride copolymer: Synthesis, characterization, paclitaxel delivery, cytotoxic effects on human ovarian and breast cancer cells

**Authors:** RAZIEH MOMEN-MESGIN, JAFAR REZAIE, VAHID NEJATI, PEYMAN NAJAFI MOGHADAM

PMC · DOI: 10.32604/or.2024.054487 · Oncology Research · 2025-02-28

## TL;DR

A new magnetic nanoparticle system was developed to deliver paclitaxel, showing better cancer cell toxicity than the drug alone.

## Contribution

A novel magnetic melamine-crosslinked polymer was developed for pH-sensitive paclitaxel delivery with enhanced cytotoxicity in cancer cells.

## Key findings

- The PSMA/Me/Fe3O4/PTX system achieved an 83% drug encapsulation efficiency.
- The nanocarrier exhibited pH-sensitive drug release behavior.
- PSMA/Me/Fe3O4/PTX showed lower IC50 values and greater cytotoxicity than free PTX in ovarian and breast cancer cells.

## Abstract

Due to systematic side effects, there is a growing interest in nanoparticle formulation of anticancer drugs. Here, we aimed to synthesize poly (styrene-alt-maleic anhydride) cross-linked by melamine (PSMA/Me) and coated with magnetite nanoparticles (MNPs) PSMA/Me/Fe3O4. In addition, we aimed to load paclitaxel (PTX) into PSMA/Me/Fe3O4 for drug delivery and anticancer investigations.

Novel PSMA/Me was synthesized via free radical copolymerization, coated with Fe3O4, and then used as a transporter for PTX delivery. Fabricated copolymer was characterized using SEM, TGA, and XRD techniques. Drug release rate and loading efficiency were investigated. Human ovarian cancer cells (Skov-3) and breast cancer cells (MCF-7 cells) were incubated with the serial concentration of either free PTX or PSMA/Me/Fe3O4/PTX for cell viability and IC50 analysis for 24 and 48 h.

Characterization methods confirmed PSMA/Me copolymer formation. The results showed a significant encapsulation efficiency of 83%. The drug release analysis exhibited that PSMA/Me/Fe3O4/PTX may be considered pH-sensitive nanocarriers. PSMA/Me/Fe3O4/PTX reduced cell viability both dose and time-dependently (p < 0.05). IC50 values of PSMA/Me/Fe3O4/PTX were low when compared to free PTX either 24 or 48 h post-treatment.

Our results indicated that PSMA/Me/Fe3O4/PTX was more cytotoxic than PTX in both cancer cells. Findings indicated the potential of PSMA/Me/Fe3O4/PTX as an anticancer nanocarrier system.

## Linked entities

- **Chemicals:** paclitaxel (PubChem CID 36314), melamine (PubChem CID 7955), styrene (PubChem CID 7501), maleic anhydride (PubChem CID 7923)
- **Diseases:** ovarian cancer (MONDO:0005140), breast cancer (MONDO:0004989)
- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** FOLH1 (folate hydrolase 1) [NCBI Gene 2346] {aka FGCP, FOLH, GCP2, GCPII, NAALAD1, PSM}
- **Diseases:** cytotoxic (MESH:D064420), ovarian and breast cancer (MESH:D061325), cancer (MESH:D009369), breast cancer (MESH:D001943), ovarian cancer (MESH:D010051)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** MCF-7 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0031), Skov-3 — Homo sapiens (Human), Ovarian serous cystadenocarcinoma, Cancer cell line (CVCL_0532)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11915072/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11915072/full.md

## References

34 references — full list in the complete paper: https://tomesphere.com/paper/PMC11915072/full.md

---
Source: https://tomesphere.com/paper/PMC11915072